Editorial: Current Challenges in Cardioembolic Stroke
- PMID: 33986722
- PMCID: PMC8112548
- DOI: 10.3389/fneur.2021.688371
Editorial: Current Challenges in Cardioembolic Stroke
Keywords: cardioembolic; cryptogenic stroke; editorial; research; stroke.
Conflict of interest statement
BF: Advisory Board (Bayer); Spearker's honoraria (BMS-Pfizer, Daichi-Sankyo); Travel grants to attend scientific meetings (Daichi-Sankyo, BMS-Pfizer), Participation in clinical trials (RESPECT-ESUS, NAVIGATE-ESUS). GN: Speaker fees/Advisory Boards/Research support from Amgen; Bayer; BMS/Pfizer; Boehringer-Ingelheim; Elpen; European Union; Galenica; Sanofi; Winmedica. JP: Research funding: Helsinki and Uusimaa Hospital District, Academy of Finland, Business Finland, St Jude Medical, Pfizer. Research collaboration: Nokia Technologies, Bittium, BcB Medical, Vital Signum; Speaker's honorary: Boehringer-Ingelheim, BMS-Pfizer, Bayer, Abbot; Advisory Board: BMS-Pfizer, Boehringer-Ingelheim, Bayer, MSD, Portola. Other: ESO guideline working group: Post-stroke hyperglycemia, secondary prevention in patients with AF. Finnish Duodecim guideline working group: ischemic stroke and TIA; Terve Media: Visiting editor.
Comment on
- Editorial on the Research Topic Current Challenges in Cardioembolic Stroke